Publicacións nas que colabora con Rafael Jose Cobas Paz (24)

2022

  1. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

2021

  1. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets

    The Lancet, Vol. 397, Núm. 10270, pp. 199-207

2020

  1. Impact of anticoagulation in patients with dementia and atrial fibrillation. Results of the CardioCHUVI-FA registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 11, pp. 877-884

  2. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction

    Revista espanola de cardiologia (English ed.), Vol. 73, Núm. 2, pp. 114-122

  3. Incidence, predictors and prognostic impact of intracranial bleeding within the first year after an acute coronary syndrome in patients treated with percutaneous coronary intervention

    European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 7, pp. 764-770

  4. Incidence, prognosis and predictors of heart failure after acute myocardial infarction

    REC: CardioClinics, Vol. 55, Núm. 1, pp. 8-14

  5. Incidence, prognosis and predictors of heart failure after acute myocardial infarction

    REC: CardioClinics, Vol. 55, Núm. 1, pp. 8-14

  6. New Cancer Diagnosis After Bleeding in Anticoagulated Patients With Atrial Fibrillation

    Journal of the American Heart Association, Vol. 9, Núm. 22, pp. e016836

  7. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects

    European heart journal. Cardiovascular pharmacotherapy, Vol. 6, Núm. 1, pp. 31-42

  8. Usefulness of Bleeding After Acute Coronary Syndromes for Unmasking Silent Cancer

    American Journal of Cardiology, Vol. 125, Núm. 12, pp. 1801-1808

  9. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation

    Journal of the American Medical Directors Association, Vol. 21, Núm. 3, pp. 367-373.e1

2019

  1. Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or Prasugrel

    Revista Espanola de Cardiologia, Vol. 72, Núm. 4, pp. 298-304

  2. Incidence, predictors and prognosis of new-onset cancer after hospital discharge for acute coronary syndrome

    REC: CardioClinics, Vol. 54, Núm. 3, pp. 148-156

  3. Incidence, predictors and prognosis of new-onset cancer after hospital discharge for acute coronary syndrome

    REC: CardioClinics, Vol. 54, Núm. 3, pp. 148-156

  4. Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI

    European Heart Journal: Acute Cardiovascular Care, Vol. 8, Núm. 6, pp. 536-542

  5. Renin–Angiotensin System Blockade and Risk of Heart Failure After Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study

    American Journal of Cardiovascular Drugs, Vol. 19, Núm. 5, pp. 487-495

  6. Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor

    Thrombosis Research, Vol. 174, pp. 51-58

  7. Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome

    Revista Espanola de Cardiologia, Vol. 72, Núm. 3, pp. 215-223

2018

  1. Assessing the performance of the PRECISE-DAPT and Paris risk scores for predicting one-year out-of-hospital bleeding in acute coronary syndrome patients

    EuroIntervention, Vol. 13, Núm. 16, pp. 1914-1922

  2. Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y12 Inhibitors in Patients With Acute Coronary Syndrome

    Revista Espanola de Cardiologia, Vol. 71, Núm. 7, pp. 538-544